Murtada Alsaif summarises a recent 4-week long phase II randomised controlled trial of ITI-007 for the treatment of schizophrenia, which contains some positive results for this novel intervention.
[read the full story...]
Joseph Hayes summarises the recent British Association for Psychopharmacology guidelines for the treatment of bipolar disorder, and compares their recommendations with those found in the NICE bipolar disorder guidance from 2014.
[read the full story...]
Angela Hassiotis and James Dove summarise a recent meta-analysis of antipsychotic prescribing and use trends in US youth with autism spectrum disorder and/or learning disabilities.
[read the full story...]
Andres Fonseca struggles to use the findings of a recent systematic review and meta-analysis of antipsychotics for the prevention and treatment of delirium in hospitalised adults.
[read the full story...]
Tayla McCloud from the #UCLJournalClub presents the findings of a cohort study showing that antipsychotics are being over-prescribed in people with learning disabilities.
[read the full story...]
John Baker summarises an updated Cochrane review on ‘as required’ PRN medication regimens for seriously mentally ill people in hospital, which finds no randomised controlled trials that support this widely used intervention.
[read the full story...]
Tracey Roberts summarises a recent RCT of the efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia.
[read the full story...]
Joanne Wallace considers a recent health technology assessment on the risks and benefits of psychotropic medication in pregnancy, which supports previous associations between valproate and adverse child outcomes.
[read the full story...]
Join us at 2-3pm on Wednesday 18th May for the #UCLJournalClub, which will be live broadcasted on YouTube and live tweeted by the @LearningDisElf
[read the full story...]
Murtada Alsaif summarises a recent network meta-analysis, which looks at the efficacy, acceptability and tolerability of antipsychotics for treatment-resistant schizophrenia.
[read the full story...]
